Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

TARIS® is advancing TAR-200 for the treatment of muscle invasive bladder cancer (MIBC). This program continuously administers the approved agent gemcitabine for multiple weeks. We believe that TAR-200 has the potential to harness both direct antitumor and immuno-oncologic activity without meaningful systemic drug exposure, yielding a powerful therapy and mitigating systemic side-effects.

List your booth number for exhibitions, ask us